278170-38-0

Upstream product

• 104605-98-3 (2S)-2-[(4-fluorophenoxy)methyl]oxirane 
• 106-95-6 allyl bromide 
• 1730-25-2 allylmagnesium bromide 
• 18123-82-5 2-(4-fluorophenoxymethyl)oxirane 
• 371-41-5 4-Fluorophenol 

Downstream Products

• 1446888-29-4 ((2S,5S)-5-((4-fluorophenoxy)methyl)tetrahydrofuran-2-yl)methanol 
• 1449521-38-3 C₁₂H₁₃FO₃ 
• 253866-88-5 (2S,5S)-2-ethynyl-5-[(4-fluorophenoxy)methyl]tetrahydrofuran 
• 220623-71-2 (2S,5S)-trans-5-((4-fluorophenoxy)methyl)-2-(1-hydroxy-3-butyn-4-yl)tetrahydrofuran 
• 253867-08-2 (2S,6S)-6-(4-fluorophenoxymethyl)-2-(4-N,O-bis-phenoxycarbonylhydroxylamino-1-butynyl)-tetrahydropyran 
• 253867-07-1 (2S,6S)-6-(4-Fluorophenoxymethyl)-2-(1-hydroxybut-3-yn-4-yl)tetrahydropyran 
• 278170-41-5 (2RS,6S)-2-(Benzenesulfonyl)-6-(4-fluorophenoxymethyl)tetrahydropyran 
• 278170-40-4 (2S)-2-(4-Fluorophenoxymethyl)-3,4-dihydro-2H-pyran 
• 278170-39-1 (2S)-2-(1-Ethenoxy)-1-(4-fluorophenoxy)hex-5-ene 

Relevant academic research and scientific papers

Stereoselective total synthesis of the potent anti-asthmatic compound CMI-977 (LDP-977)

A short and efficient stereoselective total synthesis of CMI-977 (LDP-977), a potent and orally active anti-asthmatic compound, was developed. The key steps involve a highly diastereoselective Mukaiyama oxidative cyclization, which provides the trans-THF (tetrahydrofuran) unit and a Seyferth-Gilbert homologation to construct the triple bond in the target molecule. The synthesis of the key chiral building block was performed using Jacobsen hydrolytic kinetic resolution.

A versatile approach to anti-asthmatic compound CMI-977 and its six- membered analogue

The synthesis of the anti-asthmatic compound CMI-977 is described. The tetrahydrofuran ring was effectively constructed by involving olefin metathesis while the stereoselective introduction of the 1-N- hydroxyureidylbut-3-yn-4-yl side-chain was achieved b